Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results

Joseph Pidala, MD, Kelly Walton, Hany Elmariah, MDMS, Jongphil Kim, PhD, Asmita Mishra, MD, Nelli Bejanyan, MD, Taiga Nishihori, MD, Farhad Khimani, MBBS, Lia Perez, MD, Rawan Faramand, MD, Marco L. Davila, MD PhD, Michael Nieder, MD, Nicholas Lawrence, PhD, Harshani Lawrence, PhD, Claudio Anasetti, MD, Said Sebti, PhD, Brian C. Betts, MD

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-133874

Published: 2020

Journal Articles

CD34+ Cell Dose Influences Survival after Allogeneic Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Hany Elmariah, MD MS, Syeda Mahrukh Hussnain Naqvi, MD MHS, Jongphil Kim, PhD, Taiga Nishihori, MD, Asmita Mishra, MD, Lia Perez, MD, Hien D. Liu, MD, Farhad Khimani, MD, Michael Nieder, MD, Joseph Pidala, MD, Nelli Bejanyan, MD

Blood (2019) 134 (Supplement_1): 3329.

https://doi.org/10.1182/blood-2019-129437

Published: 2019

Journal Articles

Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma

Taiga Nishihori, MD, Rachid Baz, MD, Leonel Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Frederick L. Locke, MD, Jongphil Kim, PhD, Jinming Song, MD PhD, Michael Dumala, Melissa Alsina, MD

Blood (2019) 134 (Supplement_1): 3189.

https://doi.org/10.1182/blood-2019-131451

Published: 2019

Journal Articles

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Taiga Nishihori, MD, Melissa Alsina, MD, Jose Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Rachid Baz, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Jongphil Kim, PhD, Michael Dumala, Joel G. Turner, PhD, Daniel M Sullivan, MD

Blood (2019) 134 (Supplement_1): 3314.

https://doi.org/10.1182/blood-2019-131321

Published: 2019

Journal Articles

Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome

Blood (2019) 134 (Supplement_1): 4621.

https://doi.org/10.1182/blood-2019-130922

Published: 2019

Journal Articles

Type of Therapy May Influence Outcomes in Patients over Age 70 with Acute Myeloid Leukemia: A Systematic Review of More Than 11,000 Patients

Martine Extermann, MD PhD, Marina Sehovic, MD MPH, Tea Reljic, MPH, Jongphil Kim, PhD, Jeffrey E. Lancet, MD, Benjamin Djulbegovic, MD PhD

Blood (2016) 128 (22): 3998.

https://doi.org/10.1182/blood.V128.22.3998.3998

Published: 2016

Journal Articles

Impact of Obesity in Patients with Multiple Myeloma Receiving High-Dose Melphalan Followed By Autologous Hematopoietic Cell Transplantation

Justina Ofori Frimpong, PharmD, BCOP, Rebecca Tombleson, PharmD, BCOP, Melissa Alsina, Jamie Shapiro, PharmD, BCOP, Jongphil Kim, PhD, Binglin Yue, MS, Janelle Perkins, PharmD, BCOP, Taiga Nishihori, MD

Blood (2016) 128 (22): 4636.

https://doi.org/10.1182/blood.V128.22.4636.4636

Published: 2016

Journal Articles

Beclomethasone and Budesonide Are Partially Effective As Sole Therapy for Isolated Gastro-Intestinal Gvhd

Chiara Frairia, MD, Jamie Shapiro, PharmD, Jongphil Kim, PhD, Joseph Pidala, MD PhD, Ernesto Ayala, MD, Brian C Betts, MD, Hugo F Fernandez, MD, Teresa Field, MD PhD, Mohamed Kharfan-Dabaja, MD, Frederick L Locke, MD, Asmita Mishra, MD, Taiga Nishihori, MD, Jose L Ochoa-Bayona, MD, Lia Perez, MD, Marcie L Riches, MD MS, Claudio Anasetti, MD

Blood (2014) 124 (21): 2500.

https://doi.org/10.1182/blood.V124.21.2500.2500

Published: 2014

Journal Articles

Prolonged Sirolimus Administration after Matched Related and Unrelated Allogeneic Hematopoietic Cell Transplantation Is Associated with Decreased Risk for Moderate-Severe Chronic Graft Vs. Host Disease

Joseph Pidala, MD PhD, Jongphil Kim, PhD, Melissa Alsina, MD, Ernesto Ayala, MD, Brian C Betts, MD, Hugo F Fernandez, MD, Teresa Field, MD PhD, Mohamed A Kharfan-Dabaja, MD, Frederick L Locke, MD, Asmita Mishra, MD, Taiga Nishihori, MD, Jose L Ochoa-Bayona, MD, Lia Perez, MD, Marcie L Riches, MD MS, Claudio Anasetti, MD

Blood (2014) 124 (21): 2502.

https://doi.org/10.1182/blood.V124.21.2502.2502

Published: 2014

Journal Articles

Sirolimus, Tacrolimus and Antithymocyte Globulin Are Associated with Improved Overall Survival When Compared to Methotrexate, Tacrolimus and Antithymocyte Globulin in Mismatched Unrelated Allogeneic Hematopoietic Cell Transplantation

Rebecca Nelson, PharmD, Janelle Perkins, PharmD, Jamie Shapiro, PharmD, Jongphil Kim, PhD, Binglin Yue, M.S., Claudio Anasetti, MD, Mohamed A Kharfan-Dabaja, MD

Blood (2014) 124 (21): 2553.

https://doi.org/10.1182/blood.V124.21.2553.2553

Published: 2014

Journal Articles

A Strong Correlation Between Spot Urine Protein To Creatinine Ratio and 24-Hour Urine Protein Quantification For Proteinuria Assessment In Patients With Plasma Cell Dyscrasia

Apuri Susmitha, MD, Taiga Nishihori, MD, Karen Lin, MD, Rachid Baz, MD, Binglin Yue, MS, Jongphil Kim, PhD, Kenneth H. Shain, MD, PhD, Elias Doumit, MD, Jose L Ochoa-Bayona, MD, Daniel M Sullivan, MD, Melissa Alsina, MD, Benjamin Djulbegovic, MD, PhD

Blood (2013) 122 (21): 3155.

https://doi.org/10.1182/blood.V122.21.3155.3155

Published: 2013

Journal Articles

Th17 Lymphocytes In Human Gvhd Target Tissues Are Associated With Disease Severity and Refractoriness To Systemic Glucocorticoid Therapy

Joseph Pidala, MD, MS, Elizabeth M. Sagatys, MD, Mark Lloyd, MS, Jongphil Kim, PhD, Binglin Yue, MS, Brian C Betts, MD, Claudio Anasetti, MD

Blood (2013) 122 (21): 2054.

https://doi.org/10.1182/blood.V122.21.2054.2054

Published: 2013

Journal Articles

Gene Deletions of 17p or 11q Are Independent Predictors of Decreased Progression-Free Survival and Overall Survival Following Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia

Julio Chavez, MD, Jongphil Kim, PhD, Samir Dalia, MD, Mohamed A. Kharfan-Dabaja, MD, Javier Pinilla-Ibarz, MD, PhD, Claudio Anasetti, MD, Frederick L Locke, MD

Blood (2012) 120 (21): 2007.

https://doi.org/10.1182/blood.V120.21.2007.2007

Published: 2012

Journal Articles

Updated Results of Phase II Study of Cyclophosphamide(Cy), Bortezomib(Bz), Pegylated Doxorubicin(DOX), and Dexamethasone(dex), (CVDD), in Patients with Newly Diagnosed Myeloma:an Effective Induction Regimen for High Risk Disease

Melissa Alsina, MD, Rachid Baz, MD, Kenneth H. Shain, MD, PhD, Leonel Ochoa, MD, Taiga Nishihori, MD, Daniel M Sullivan, MD, Binglin Yue, Jongphil Kim, PhD, William Dalton, PhD, MD

Blood (2012) 120 (21): 4071.

https://doi.org/10.1182/blood.V120.21.4071.4071

Published: 2012

Journal Articles

Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd

Joseph Pidala, MD, MS, Jongphil Kim, PhD, Heather Jim, PhD, Hugo F. Fernandez, MD, Marcie Tomblyn, MD, MS, Mohamed A Kharfan-Dabaja, MD, Brian C. Betts, MD, Taiga Nishihori, MD, Mian Xu, William E. Janssen, PhD, Frederick L Locke, MD, Ernesto Ayala, MD, Lia Perez, MD, Janelle Perkins, PharmD, Teresa Field, MD, PhD, Leonel Ochoa, Melissa Alsina, MD, Claudio Anasetti, MD

Blood (2011) 118 (21): 323.

https://doi.org/10.1182/blood.V118.21.323.323

Published: 2011

Journal Articles

Comparison of Sirolimus and Mycophenolate Mofetil As Salvage Treatment for Acute Graft-Versus-Host Disease

Taiga Nishihori, MD, Joseph Pidala, MD, MS, Jongphil Kim, PhD, Marcie Tomblyn, MD, MS, Claudio Anasetti, MD

Blood (2011) 118 (21): 4548.

https://doi.org/10.1182/blood.V118.21.4548.4548

Published: 2011

Journal Articles

Maximally Tolerated Busulfan Area Under the Concentration-Time Curve (AUC) In Combination with Fludarabine as Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.

Janelle Perkins, PharmD, Teresa Field, MD, PhD, Jongphil Kim, PhD, Hugo F. Fernandez, MD, Lia Perez, MD, Ernesto Ayala, MD, Mohamed Kharfan-Dabaja, MD, Marcie Tomblyn, MD, MS, Daniel Sullivan, MD, Claudio Anasetti, MD

Blood (2010) 116 (21): 3499.

https://doi.org/10.1182/blood.V116.21.3499.3499

Published: 2010

Journal Articles

Sirolimus Yields High Response Rates in Hematopoietic Allograft Recipients with Steroid-Refractory Acute Graft-Versus-Host Disease.

Joseph A. Pidala, MD, Daanish Hoda, Norma Salgado-Vila, Jongphil Kim, PhD, Janelle Perkins, PharmD, Ryan Bookout, PharmD, Teresa Field, MD, PhD, Lia Perez, MD, Ernesto Ayala, MD, J. Leonel Ochoa-Bayona, Jyotishankar Raychaudhuri, Melissa Alsina, MD, John N Greene, MD, William E. Janssen, PhD, Hugo F. Fernandez, MD, Claudio Anasetti, MD, Mohamed A Kharfan-Dabaja, MD

Blood (2009) 114 (22): 2235.

https://doi.org/10.1182/blood.V114.22.2235.2235

Published: 2009

Journal Articles

Targeted Intravenous Busulfan and Fludarabine Allogeneic Transplantation Conditioning in Acute Myeloid Leukemia.

Joseph A. Pidala, MD, Jongphil Kim, PhD, Claudio Anasetti, MD, Melissa Alsina, MD, Ernesto Ayala, MD, Teresa Field, MD, PhD, Mohamed A Kharfan-Dabaja, MD, Jose L Ochoa, MD, Lia Perez, MD, Janelle Perkins, PharmD, Marcie Tomblyn, MD, MS, Hugo F. Fernandez, MD

Blood (2009) 114 (22): 2290.

https://doi.org/10.1182/blood.V114.22.2290.2290

Published: 2009

Journal Articles

Pharmacokinetically Targeted Intravenous Busulfan Combined with Fludarabine (BuFlu) as Conditioning Prior to Allogeneic Peripheral Blood Hematopoietic Cell Transplant: Pretransplant Predictors of Outcomes.

Janelle Perkins, PharmD, Jongphil Kim, PhD, Claudio Anasetti, MD, Mohamed A Kharfan-Dabaja, MD, Ernesto Ayala, MD, Lia Perez, MD, Hugo Fernandez, MD, Karen Fancher, PharmD, Cheryl Tate, PharmD, Teresa Field, MD

Blood (2009) 114 (22): 3347.

https://doi.org/10.1182/blood.V114.22.3347.3347

Published: 2009

NARROW

Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results

CD34+ Cell Dose Influences Survival after Allogeneic Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome

Type of Therapy May Influence Outcomes in Patients over Age 70 with Acute Myeloid Leukemia: A Systematic Review of More Than 11,000 Patients

Impact of Obesity in Patients with Multiple Myeloma Receiving High-Dose Melphalan Followed By Autologous Hematopoietic Cell Transplantation

Beclomethasone and Budesonide Are Partially Effective As Sole Therapy for Isolated Gastro-Intestinal Gvhd

Prolonged Sirolimus Administration after Matched Related and Unrelated Allogeneic Hematopoietic Cell Transplantation Is Associated with Decreased Risk for Moderate-Severe Chronic Graft Vs. Host Disease

Sirolimus, Tacrolimus and Antithymocyte Globulin Are Associated with Improved Overall Survival When Compared to Methotrexate, Tacrolimus and Antithymocyte Globulin in Mismatched Unrelated Allogeneic Hematopoietic Cell Transplantation

A Strong Correlation Between Spot Urine Protein To Creatinine Ratio and 24-Hour Urine Protein Quantification For Proteinuria Assessment In Patients With Plasma Cell Dyscrasia

Th17 Lymphocytes In Human Gvhd Target Tissues Are Associated With Disease Severity and Refractoriness To Systemic Glucocorticoid Therapy

Gene Deletions of 17p or 11q Are Independent Predictors of Decreased Progression-Free Survival and Overall Survival Following Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia

Updated Results of Phase II Study of Cyclophosphamide(Cy), Bortezomib(Bz), Pegylated Doxorubicin(DOX), and Dexamethasone(dex), (CVDD), in Patients with Newly Diagnosed Myeloma:an Effective Induction Regimen for High Risk Disease

Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd

Comparison of Sirolimus and Mycophenolate Mofetil As Salvage Treatment for Acute Graft-Versus-Host Disease

Maximally Tolerated Busulfan Area Under the Concentration-Time Curve (AUC) In Combination with Fludarabine as Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.

Sirolimus Yields High Response Rates in Hematopoietic Allograft Recipients with Steroid-Refractory Acute Graft-Versus-Host Disease.

Targeted Intravenous Busulfan and Fludarabine Allogeneic Transplantation Conditioning in Acute Myeloid Leukemia.

Pharmacokinetically Targeted Intravenous Busulfan Combined with Fludarabine (BuFlu) as Conditioning Prior to Allogeneic Peripheral Blood Hematopoietic Cell Transplant: Pretransplant Predictors of Outcomes.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only